Carter Copeland
Medical · San Diego, CANPI 1003560939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 855 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,497, 2.3 times the $2,403 reported in 2022. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 855 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- AbbVie$2K
- Lundbeck LLC$1K
- Biogen$889
- Neurelis, Inc.$860
- Amgen$840
- plus $9K from 53 others
What the payments were for
- Food & beverage$16,84299%
- Education$1911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$230
- EVRYSDI$149
- AIMOVIG$124
- NURTEC ODT$114
- VALTOCO$102
How this compares
$17,033 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 19 | $362,692 |
| Emgality PenGalcanezumab-Gnlm | 76 | $51,453 |
| Nurtec OdtRimegepant Sulfate | 37 | $35,708 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $22,763 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $8,508 |
| Memantine Hcl | 147 | $6,132 |
| Gabapentin | 175 | $1,637 |
| Levetiracetam | 59 | $1,423 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 37 | $1,357 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 79 | $1,280 |
| Donepezil Hcl | 93 | $975 |
| Lacosamide | 17 | $871 |
| ValacyclovirValacyclovir Hcl | 31 | $841 |
| Potassium Chloride | 25 | $420 |
| Amitriptyline Hcl | 59 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $182 | $362,69219 claims |
| PfizerNurtec Odt | $664 | $35,70837 claims |
| Upsher-smith Laboratories LLCTopiramate | $32 | $32269 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in San Diego
- Cheryl KyinnSan Diego$103K
- Touraj YariSan Diego$27K
- Aaron WillcottSan Diego$23K
- Yuchao JinSan Diego$22K
- Cameron ChanSan Diego$16K
- Melanie GloverSan Diego$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.